Concentration-response relationship for fluvoxamine using remission as an endpoint: A receiver operating characteristics curve analysis in major depression

Journal of Clinical Psychopharmacology

Volumn 28, Issue 3, 2008, Pages 325-328

  Suzuki, Yutaro ^a   Fukui, Naoki ^a   Sawamura, Kazushi ^a   Sugai, Takuro ^a   Watanabe, Junzo ^a   Ono, Shin ^a   Inoue, Yoshimasa ^b   Ozdemir, Vural ^c   Someya, Toshiyuki ^a  

^a NIIGATA UNIVERSITY GRADUATE SCHOOL OF MEDICAL AND DENTAL SCIENCES   (Japan)

^b MP Technopharma Corporation Technology Department   (Japan)

^c UNIVERSITÉ DE MONTRÉAL   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

FLUVOXAMINE; ANTIDEPRESSANT AGENT;

ADOLESCENT; ADULT; ARTICLE; CONCENTRATION RESPONSE; CONTROLLED STUDY; DISEASE SEVERITY; DRUG BLOOD LEVEL; DRUG DOSE TITRATION; FEMALE; HAMILTON SCALE; HUMAN; MAJOR CLINICAL STUDY; MAJOR DEPRESSION; MALE; OUTPATIENT; PREDICTIVE VALIDITY; PREDICTOR VARIABLE; PRIORITY JOURNAL; PROSPECTIVE STUDY; RECEIVER OPERATING CHARACTERISTIC; REMISSION; TREATMENT DURATION; ADJUSTMENT DISORDER; BLOOD; DEPRESSION; DOSE RESPONSE; DRUG ADMINISTRATION; MIDDLE AGED; PERSONALITY TEST; ROC CURVE; TREATMENT OUTCOME;

ADJUSTMENT DISORDERS; ADULT; ANTIDEPRESSIVE AGENTS, SECOND-GENERATION; DEPRESSIVE DISORDER; DEPRESSIVE DISORDER, MAJOR; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; FEMALE; FLUVOXAMINE; HUMANS; MALE; MIDDLE AGED; PERSONALITY INVENTORY; PROSPECTIVE STUDIES; ROC CURVE; TREATMENT OUTCOME;

EID: 51449089976     PISSN: 02710749     EISSN: None     Source Type: Journal    
DOI: 10.1097/JCP.0b013e3181730850     Document Type: Article

References (15)

1. Rasmussen BB, Brøsen K. Is therapeutic drug monitoring a case for optimizing clinical outcome and avoiding interactions of selective serotonin reuptake inhibitor? Ther Drug Monit. 2000;22:143-154.
2. Mintz J, Mintz LI, Arruda MJ, et al. Treatments of depression and the functional capacity to work. Arch Gen Psychiatry. 1992;49:761-768.
3. Wilcox CS, Cohn JB, Linden RD, et al. Predictors of placebo response: a retrospective analysis. Psychopharmacol Bull. 1992;28:157-162.
4. Brown WA, Johnson MF, Chen MG. Clinical features of depressed patients who do and do not improve with placebo. Psychiatry Res. 1992; 41:203-214.
5. Suzuki Y, Sawamura K, Someya T. The effects of a 5-hydroxytryptamine 1A receptor gene polymorphism on the clinical response to fluvoxamine in depressed patients. Pharmacogenomics J. 2004;4:283-286.
6. Serretti A, Artioli P, Lorenzi C, et al. The C(-1019)G polymorphism of the 5-HT1A gene promoter and antidepressant response in mood disorders: preliminary findings. Int J Neuropsychopharmacol. 2004;7: 453-460.
7. Härtter S, Wetzel H, Hammes E, et al. Serum concentrations of fluvoxamine and clinical effects. A prospective open clinical trial. Pharmacopsychiatry. 1998;31:199-200.
8. Nathan RS, Perel JM, Pollock BG, et al. The role of neuropharmacologic selectivity in antidepressant action: fluvoxamine versus desipramine. J Clin Psychiatry. 1990;51:367-372.
9. Gerstenberg G, Aoshima T, Fukasawa T, et al. Relationship between clinical effects of fluvoxamine and the steady-state plasma concentrations of fluvoxamine and its major metabolite fluvoxamino acid in Japanese depressed patients. Psychopharmacology. 2003;167:443-448.
10. De Wilde JEM, Doogan DP. Fluvoxamine and clomipramine in endogenous depression. J Affect Disord. 1982;4:249-259.
11. Kasper S, Dotsch M, Kick H, et al. Plasma concentration of fluvoxamine and maprotiline in major depression: implications on therapeutic efficacy and side effects. Eur Neuropsychopharmacol. 1993;3:13-21.
12. Lotrich FE, Bies RR, Smith GS, et al. Relevance of assessing drug concentration exposure in pharmacogenetic and imaging studies. J Psychopharmacol. 2006;20(suppl 4):33-40.
13. Suhara T, Takano A, Sudo Y, et al. High levels of serotonin transporter occupancy with low-dose clomipramine in comparative occupancy study with fluvoxamine using positron emission tomography. Arch Gen Psychiatry. 2003;60:386-391.
14. Adli M, Baethge C, Heinz A, et al. Is dose escalation of antidepressants a rational strategy after a medium-dose treatment has failed? Eur Arch Psychiatry Clin Neurosci. 2005;255:387-400.
15. Baker CB, Woods SW. Is there a SSRI dose response in treating major depression? The case for re-analysis of current data and for enhancing future study design. Depress Anxiety. 2003;17:10-18.